Gapping up
In reaction to strong earnings/guidance:
- BOOT +12.1%, AMAT +4.4%, HUYA +1.8%, SMCI +1%
M&A news:
- CRAY +16.6% (to be acquired by Hewlett Packard Enterprise (HPE) for $35.00 per share in cash)
Other news:
- ACHN +7.2% (reports interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor ACH-4471 in combination with intravenous eculizumab)
- LGF.A +2.9% (light volume; scheduled to report earnings next week)
- MNKD +2.4% (entered into exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific for the commercialization of Afrezza Inhalation Powder in Australia)
- NOG +2.1% (Pres disclosed the purchase of 200K shares)
- INO +1.5% (Inovio and QIAGEN establish collaboration to develop diagnostic test for VGX-3100, Inovio's novel immunotherapy targeting advanced cervical pre-cancer)
- ENDP +1.5% (to present clinical data from Phase 3 investigational study of collagenase clostridium histolyticum for the treatment of cellulite)
- EIX +1.3% (established an $1.5 bln common stock at-the-market equity distribution program and forward sales agreements)
- HROW +1% (discloses conclusion of Allergan (AGN) lawsuit)
Analyst comments:
- UAA +4.2% (upgraded to Overweight from Neutral at JP Morgan)
- CONE +0.8% (upgraded to Buy from Hold at Deutsche Bank)
- FL +0.8% (upgraded to Buy from Neutral at B. Riley FBR)